Abstract
Pimecrolimus and tacrolimus represent the first members of a new class of medications, calcineurin inhibitors. These topical macrolide immunomodulators have been successfully introduced in the treatment of atopic dermatitis. They inhibit T cell proliferation, mast cell degranulation, production and release of IL-2, IL-4, IF-γ and TNF-α. They do not effect endothelial cells and fibroblasts, so they do not induce skin atrophy. In several studies, it has been shown that topical pimecrolimus and tacrolimus are effective, well tolerated and safe in both adults and children with atopic dermatitis. Pimecrolimus permeates less through the skin than tacrolimus and much less than corticosteroids. It has a lower potential for transcutaneous absorption resulting in a lower risk of systemic effects. In addition, they have been used in other inflammatory skin diseases including psoriasis, lichen planus, seborrheic dermatitis, allergic contact dermatitis, vitiligo, pyoderma gangrenosum, alopecia areata, graft versus host disease, akne rosacea, etc. In this review article mechanism of action, efficacy, safety of pimecrolimus and tacrolimus, and future directions of these immunomodulators were discussed.
Keywords: Topical therapy, topical macrolide immunomodulator, calcineurin inhibitor, pimecrolimus, tacrolimus
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Topical Calcineurin Inhibitors, Pimecrolimus and Tacrolimus
Volume: 6 Issue: 3
Author(s): Aylin Turel Ermertcan and Serap Ozturkcan
Affiliation:
Keywords: Topical therapy, topical macrolide immunomodulator, calcineurin inhibitor, pimecrolimus, tacrolimus
Abstract: Pimecrolimus and tacrolimus represent the first members of a new class of medications, calcineurin inhibitors. These topical macrolide immunomodulators have been successfully introduced in the treatment of atopic dermatitis. They inhibit T cell proliferation, mast cell degranulation, production and release of IL-2, IL-4, IF-γ and TNF-α. They do not effect endothelial cells and fibroblasts, so they do not induce skin atrophy. In several studies, it has been shown that topical pimecrolimus and tacrolimus are effective, well tolerated and safe in both adults and children with atopic dermatitis. Pimecrolimus permeates less through the skin than tacrolimus and much less than corticosteroids. It has a lower potential for transcutaneous absorption resulting in a lower risk of systemic effects. In addition, they have been used in other inflammatory skin diseases including psoriasis, lichen planus, seborrheic dermatitis, allergic contact dermatitis, vitiligo, pyoderma gangrenosum, alopecia areata, graft versus host disease, akne rosacea, etc. In this review article mechanism of action, efficacy, safety of pimecrolimus and tacrolimus, and future directions of these immunomodulators were discussed.
Export Options
About this article
Cite this article as:
Aylin Turel Ermertcan and Serap Ozturkcan , Topical Calcineurin Inhibitors, Pimecrolimus and Tacrolimus, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2007; 6 (3) . https://dx.doi.org/10.2174/187152307781368300
DOI https://dx.doi.org/10.2174/187152307781368300 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Pharmacological Primer of Biased Agonism
Endocrine, Metabolic & Immune Disorders - Drug Targets Sphingolipids in Genetic and Acquired Forms of Chronic Kidney Diseases
Current Medicinal Chemistry Established and In-trial GPCR Families in Clinical Trials: A Review for Target Selection
Current Drug Targets The Circulating Endothelial Cell in Cancer: Towards Marker and Target Identification
Current Pharmaceutical Design Regulation of Adrenomedullin and its Family Peptide by RAMP System – Lessons from Genetically Engineered Mice
Current Protein & Peptide Science EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Current Cancer Drug Targets miR-1247 is Correlated with Prognosis of Pancreatic Cancer and Inhibits Cell Proliferation by Targeting Neuropilins
Current Molecular Medicine Structural Basis for Binding of Aurora-A<sup>G198N</sup>- INCENP Complex: MD Simulations and Free Energy Calculations
Protein & Peptide Letters The Involvement of Lysosomes in Myocardial Aging and Disease
Current Cardiology Reviews Meet Our Editorial Board Member:
Recent Patents on Biomarkers The Chick Embryo Chorioallantoic Membrane as a Model for in vivo Research on Anti-Angiogenesis
Current Pharmaceutical Biotechnology On the Interaction of β-Amyloid Peptides and α7-Nicotinic Acetylcholine Receptors in Alzheimer’s Disease
Current Alzheimer Research Improved Anti-Tumor Activity of Novel Highly Bioactive Liposome-Bound TRAIL in Breast Cancer Cells
Recent Patents on Anti-Cancer Drug Discovery The ‘Other’ Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Metabolic and Functional Brain Mapping, Connectivity and Plasticity Applied to the Surgery of Cerebral Tumors
Current Medical Imaging Surface Markers of Cancer Stem Cells in Solid Tumors
Current Stem Cell Research & Therapy Strategies that Target Tight Junctions for Enhanced Drug Delivery
Current Pharmaceutical Design The role of Nox-mediated oxidation in the regulation of cytoskeletal dynamics
Current Pharmaceutical Design C-11 Radiochemistry in Cancer Imaging Applications
Current Topics in Medicinal Chemistry Therapeutic Targets in Triple Negative Breast Cancer - Where are we now?
Recent Patents on Anti-Cancer Drug Discovery